UCBJF (UCBJF) Stock Price & Analysis
UCBJF (UCBJF) rose 2.03% to USD 290 as of June 10, 2026 at 00:55 UTC, according to Nexqual real-time market data.
UCBJF last closed at USD 284.24; the session ranged USD 290–290 on volume of 165 shares. Market capitalization is $55.20B, with a 52-week range of USD 178.54–345.39 (PNK). Source: Nexqual, June 10, 2026 at 00:55 UTC.
Key Statistics (as of June 10, 2026 at 00:55 UTC)
| Price | USD 290 |
|---|---|
| Change | ▲ 2.03% (up) |
| Previous Close | USD 284.24 |
| Open | USD 290 |
| Day Range | USD 290 – 290 |
| 52-Week Range | USD 178.54 – 345.39 |
| Volume | 165 shares |
| Market Cap | $55.20B |
| Exchange | PNK |
Technical Analysis (UCBJF)
Nexqual's technical model rates UCBJF "NEUTRAL" based on 3 bullish and 2 bearish signals across 123 daily candles, as of June 10, 2026 at 00:55 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 49.33 (neutral) |
| vs SMA50 | Below (USD 294.13) |
| MACD | 2.63 (positive) |
Analyst Ratings (UCBJF)
Wall Street analysts rate UCBJF "None", per Nexqual as of June 10, 2026 at 00:55 UTC.
| Consensus Rating | None |
|---|
Earnings (UCBJF)
| Next Earnings Date | 2026-07-30 |
|---|
Source: Nexqual, June 10, 2026 at 00:55 UTC.
Financials & Fundamentals (UCBJF)
| Total Revenue | $7.74B |
|---|---|
| Revenue Growth (YoY) | +26.60% |
| Gross Margin | +74.29% |
| Operating Margin | +30.39% |
| Profit Margin | +20.13% |
| ROE | +14.91% |
| Debt / Equity | 20.66 |
| Current Ratio | 1.38 |
| Total Cash | $2.36B |
| Total Debt | $2.24B |
| Free Cash Flow | $1.83B |
Source: Nexqual, June 10, 2026 at 00:55 UTC.
Financial Health Score (UCBJF)
Nexqual rates UCBJF's overall financial health "Strong" across five dimensions, as of June 10, 2026 at 00:55 UTC.
| Growth | Strong — Revenue +26% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 74%, operating 30% |
| Balance Sheet | Strong — $2.36B cash vs $2.24B debt, net cash position |
| Cash Flow | Strong — FCF $1.83B, 24% margin |
| Efficiency | Mixed — ROE 15%, ROA 7.0% |
Ownership (UCBJF)
| Insider Ownership | +36.28% |
|---|---|
| Institutional Ownership | +41.34% |
| Shares Outstanding | 190.36M |
| Float | 119.86M |
Source: Nexqual, June 10, 2026 at 00:55 UTC.
Leadership (UCBJF)
UCBJF is led by Jean-Christophe Tellier (age 66), CEO & Executive Director, per Nexqual as of June 10, 2026 at 00:55 UTC.
| CEO & Executive Director | Jean-Christophe Tellier (age 66) |
|---|---|
| Executive VP & CFO | Sandrine Dufour (age 59) |
| Executive VP & Chief Scientific Officer | Alistair Henry (age 58) |
| Executive Vice President of Patient Evidence | Emmanuel Caeymaex (age 56) |
| Executive Vice President of Patient Supply | Kirsten Lund-Jurgensen (age 66) |
Major Backers & Investors (UCBJF)
Notable institutional backers of UCBJF include Fidelity, according to Nexqual as of June 10, 2026 at 00:55 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 2.88% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.03% |
| BlackRock | 0.46% |
Source: Nexqual, June 10, 2026 at 00:55 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| UCBJY | UCB S.A. | USD 151.74 | ▲ 1.47% |
| GNMSF | Genmab A/S | USD 249 | ▼ 0.18% |
| CMXHF | CSL Ltd. | USD 66 | ▼ 6.44% |
| CSLLY | CSL Ltd. | USD 17.44 | ▲ 1.87% |
| MKGAF | Merck KGaA | USD 159.71 | ▼ 2.48% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:55 UTC. This page is informational and not investment advice.